Trial Profile

A Phase 1 Open-label, Radiolabeled, Single-dose Study To Investigate The Metabolism Of [14c]Lorlatinib (Pf-06463922) In Healthy Male Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lorlatinib (Primary)
Indications Cancer; Neuroblastoma; Non-small cell lung cancer
Focus Pharmacokinetics
Sponsors Pfizer

Most Recent Events

22 May 2020 Results from NCT03184168 and NCT02564562 evaluating Metabolism, Excretion, and Pharmacokinetics of Lorlatinib (PF-06463922) and Evaluation of the Impact of Radiolabel Position and Other Factors on Comparability, published in the Journal of Clinical Pharmacology
16 Mar 2019 Comparison of data from the 2 ADME studies conducted for lorlatinib presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
11 Sep 2017 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com